Nordea Investment Management AB Increases Stake in Haemonetics Corporation $HAE

Nordea Investment Management AB increased its holdings in Haemonetics Corporation (NYSE:HAE) by 0.2% in the second quarter, Holdings Channel reports. The fund owned 103,721 shares of the medical instruments supplier’s stock after purchasing an additional 221 shares during the quarter. Nordea Investment Management AB’s holdings in Haemonetics were worth $7,705,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Quarry LP raised its holdings in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares in the last quarter. GAMMA Investing LLC raised its stake in Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 165 shares in the last quarter. UMB Bank n.a. raised its stake in Haemonetics by 91.7% in the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 320 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in Haemonetics during the first quarter worth $65,000. Finally, CWM LLC boosted its position in Haemonetics by 53.5% during the 2nd quarter. CWM LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $136,000 after acquiring an additional 637 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on HAE. Barrington Research reissued an “outperform” rating and issued a $86.00 price target on shares of Haemonetics in a research report on Tuesday, September 23rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Haemonetics in a report on Wednesday, October 8th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $62.00 price target (down from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Mizuho cut their price objective on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Finally, Raymond James Financial cut shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and decreased their target price for the company from $105.00 to $78.00 in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and an average price target of $75.89.

Haemonetics Stock Up 0.9%

NYSE:HAE opened at $50.70 on Tuesday. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $94.99. The company has a market cap of $2.44 billion, a PE ratio of 15.50, a P/E/G ratio of 0.93 and a beta of 0.37. The company’s 50 day moving average is $51.85 and its two-hundred day moving average is $62.63.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping the consensus estimate of $1.01 by $0.09. The business had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.